Immunic announced first patients enrolled in investigator-sponsored phase 2 clinical trial of IMU-838 in combination with Oseltamivir for treatment of patients with COVID-19
| |

Immunic announced first patients enrolled in investigator-sponsored phase 2 clinical trial of IMU-838 in combination with Oseltamivir for treatment of patients with COVID-19

On Jul. 27, 2020, Immunic announced enrollment of the first patients in an investigator-sponsored phase 2 clinical trial…